Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense neoadjuvant chemotherapy plus CCRT versus CCRT alone for locally advanced cervical cancer
ChiCTR1900025327Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and paclitaxel in Cervical Cancer (CC) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Disease-free survival, Overall survival and 2 more. Started Jan 2019; status: recruiting.
02
Drugs
cisplatinpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900025327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025327.